Compare Tempus AI (TEM) vs 22nd Century Group Inc (XXII) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Tempus AI vs 22nd Century Group Inc — how do they compare? Tempus AI trades at $54.66 (market cap $10.05B), while 22nd Century Group Inc trades at $4.46 (market cap $1.52M). The key difference: Tempus AI is far larger — about 6611.8× 22nd Century Group Inc's market cap, and Tempus AI is trading nearer its 52-week high, 22nd Century Group Inc nearer its low. Which is the better fit depends on your goals.
| TEM | XXII | |
|---|---|---|
Market Cap | $10.05B | $1.52M |
Sector | Broad Market / Factor | Technology |
52-Week High | $103.25 | $801.00 |
52-Week Low | $41.55 | $3.72 |
Enterprise Value | $10.68B | -$6.71M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Tempus AI (TEM) trades at $54.99, down 0.13% on the day, with a bullish technical signal and strong analyst support. Recent Q2 2026 results showed a narrower loss than expected and revenue beat, driving positive sentiment. The company is expanding through acquisitions like Personalis and launching new services, though it remains unprofitable with negative margins.
The outlook is cautiously optimistic due to revenue growth and strategic initiatives, but high valuation ratios and persistent losses pose risks. Upside is supported by a $61.57 consensus price target, while competitive and execution challenges require monitoring for sustained investor confidence.
XXII trades at $4.46, up 2.53% today, with a neutral technical signal and bearish moving averages. The company shows deep losses with a net income margin of -65.76% and negative ROE of -130.19%, though it beat earnings in Q3 2025. Recent news highlights VLN® retail expansion in California and New York, and a reverse stock split on June 12, 2026. Cash flow remains dependent on financing, with operating cash flow negative at -$7.72 million in 2025.
Outlook is speculative; analyst consensus is 75% buy with growth potential from VLN® market expansion, but high execution and regulatory risks persist. Investment hinges on revenue scaling to offset persistent losses, with stock volatility expected near key resistance at $5.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Tempus AI
Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.
Read more on TEM →About 22nd Century Group Inc
22nd Century Group is a plant biotechnology company that uses genetic engineering and gene editing to control the levels of nicotine in tobacco plants. Its flagship product line, VLN®, is the first and only combustible cigarette authorized by the FDA as a Modified Risk Tobacco Product (MRTP), containing 95% less nicotine than traditional cigarettes to help adult smokers smoke less.
Read more on XXII →
